Showing results (221-230 of 241) with videos related to
Sort By:
Pageof 25
BMJ Open|June 27, 2023
Music to prevent deliriUm during neuroSurgerY (MUSYC): a single-centre, prospective randomised controlled trialPablo R Kappen, M I Mos, Johannes Jeekel, et al.The Lancet. Haematology|August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trialJustin Taylor, Xiaoli Mi, Alexander V Penson, et al.Nature Biotechnology|March 24, 2015
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cellsAndriana G Kotini, Chan-Jung Chang, Ibrahim Boussaad, et al.Cancer Discovery|March 5, 2014
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignanciesOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, et al.Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
Islet amyloid deposition limits the viability of human islet grafts but not porcine islet graftsK J Potter, A Abedini, P Marek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.Cancer|August 10, 2021
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementationErica D Warlick, Celalettin Ustun, Astrid Andreescu, et al.British Journal of Cancer|March 20, 2003
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimenJ Kupryjańczyk, T Szymańska, R Madry, et al.Nature Medicine|September 19, 2017
The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cellsLy P Vu, Brian F Pickering, Yuanming Cheng, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimensJ Plisiecka-Hałasa, G Karpińska, T Szymańska, et al.Pageof 25